NASDAQ:KLRA Kailera Therapeutics Q1 2026 Earnings Report $13.94 -0.97 (-6.51%) As of 09/11/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Kailera Therapeutics EPS ResultsActual EPS-$3,650.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AKailera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKailera Therapeutics Announcement DetailsQuarterQ1 2026Date5/26/2026TimeAfter Market ClosesConference Call DateTuesday, May 26, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Kailera Therapeutics Earnings HeadlinesKailera Therapeutics (NASDAQ:KLRA) Reaches New 52-Week Low - Should You Sell?September 12 at 3:41 AM | americanbankingnews.comKailera Therapeutics Stock Price HistoryAugust 26, 2026 | investing.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot IgnoreAugust 18, 2026 | 247wallst.comKailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?August 17, 2026 | uk.finance.yahoo.comKailera Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 12, 2026 | markets.businessinsider.comSee More Kailera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kailera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kailera Therapeutics and other key companies, straight to your email. Email Address About Kailera TherapeuticsKailera Therapeutics (NASDAQ:KLRA) is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders. Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use. The company’s operations are centered on the development of therapies for global markets. Publicly available information about Kailera Therapeutics’ broader pipeline, geographic operations and leadership team is limited.View Kailera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
